| Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment (NCT02056587) | Kidney Cancer Research Bureau | 2011-11-01 |
| Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma (NCT01491672) | Novartis Pharmaceuticals | 2011-11-01 |
| PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy (NCT01415167) | Prometheus Laboratories | 2011-08-01 |
| Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma (NCT01223027) | Novartis Pharmaceuticals | 2011-03-01 |
| Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2) (NCT01266837) | iOMEDICO AG | 2011-03-01 |
| IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma (NCT01265901) | Immatics Biotechnologies GmbH | 2010-12-01 |
| Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma (NCT01342627) | Centro di Riferimento Oncologico - Aviano | 2010-10-01 |
| Phase II Study of Alternating Sunitinib and Temsirolimus (NCT01517243) | Dartmouth-Hitchcock Medical Center | 2010-09-22 |
| A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment (NCT01136733) | Eisai Inc. | 2010-08-05 |
| Multicenter Dose-escalation Study of a Combination of Pazopanib and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors (NCT01202032) | Centre Leon Berard | 2010-07-01 |
| Cost Effectiveness Of Sunitinib In Central America And Caribbean (NCT01033981) | Pfizer | 2010-05-01 |
| Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer (NCT01152801) | Novartis Pharmaceuticals | 2010-05-01 |
| Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients (NCT01073644) | Pfizer | 2010-02-01 |
| Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma (NCT01481870) | Yamagata University | 2010-01-01 |
| Vascular Endothelial Growth Factor (VEGF) Imaging Before and During Everolimus Treatment for Renal Cell Carcinoma (NCT01028638) | University Medical Center Groningen | 2009-12-01 |
| Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer (NCT01274273) | University of Aarhus | 2009-10-01 |
| Clinical Trial to Assess the Importance of Nephrectomy (NCT00930033) | Assistance Publique - Hôpitaux de Paris | 2009-09-09 |
| Serum CA9 Level as Biological Marker of the Treatment Response in Metastatic Renal Cell Cancer (NCT00942058) | Centre Hospitalier Universitaire de Saint Etienne | 2009-06-01 |
| Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients (NCT00913913) | Dartmouth-Hitchcock Medical Center | 2009-02-01 |
| Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma (NCT00930345) | Assistance Publique - Hôpitaux de Paris | 2008-12-01 |
| Study of Sorafenib in Patients With Advanced Renal Cell Carcinoma (NCT00848640) | Egyptian Foundation For Cancer Research | 2008-10-01 |
| Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma (NCT00414765) | Novartis Pharmaceuticals | 2008-09-03 |
| A Phase II Study of AS1411 in Renal Cell Carcinoma (NCT00740441) | Antisoma Research | 2008-08-01 |
| A Study for Participants With Metastatic Renal Cell Carcinoma (NCT00709995) | Eli Lilly and Company | 2008-06-30 |
| Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT® (NCT00684645) | Pfizer | 2008-06-01 |
| Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell Carcinoma (NCT01219751) | Asan Medical Center | 2008-06-01 |
| Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma (NCT00619268) | Centre Leon Berard | 2008-02-01 |
| Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma (NCT00625768) | Antisoma Research | 2008-01-01 |
| Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer (NCT00357760) | National Cancer Institute (NCI) | 2007-12-01 |
| A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma (NCT00515697) | Eli Lilly and Company | 2007-11-01 |
| Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC) (NCT00570882) | Asan Medical Center | 2007-10-01 |
| Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients (NCT01182142) | Kidney Cancer Research Bureau | 2007-09-01 |
| A SU011248 Expanded Access Protocol for Systemic Therapy of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible for Participation in Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248 (NCT00531544) | King Faisal Specialist Hospital & Research Center | 2007-02-01 |
| Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma (NCT00444314) | CASI pharmaceuticals, Inc. | 2007-02-01 |
| RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib (NCT00410124) | Novartis Pharmaceuticals | 2006-11-01 |
| The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma (NCT00554515) | Beth Israel Deaconess Medical Center | 2006-11-01 |
| Matched Unrelated Donor Transplant for Metastatic Renal Cell Carcinoma (NCT00318110) | Center for International Blood and Marrow Transplant Research | 2006-04-01 |
| A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients (NCT00421512) | Memorial Sloan Kettering Cancer Center | 2006-03-01 |
| Phase I/II Dose-escalation Study of Lutetium-177-labeled cG250 in Patients With Advanced Renal Cancer (NCT00142415) | Ludwig Institute for Cancer Research | 2005-02-01 |
| Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma (NCT00630409) | University of Pittsburgh | 2004-09-01 |
| MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma (NCT00606866) | University of Chicago | 2004-07-01 |
| Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma (NCT00068393) | Eastern Cooperative Oncology Group | 2004-02-24 |
| Efficacy of Activated Lymphocytes in Renal Cell Carcinoma. (NCT00151645) | Rennes University Hospital | 2003-12-01 |
| Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma (NCT01689766) | Endocyte | 2003-11-01 |
| Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma (NCT00203866) | University of Chicago | 2003-10-01 |
| Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Suspected Metastatic Renal Cell Carcinoma (NCT01689662) | Endocyte | 2002-08-01 |
| Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis (NCT00291369) | Centre Leon Berard | 1999-12-01 |